Tuesday, 17 Nov 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US

SHA: 688356

  • #
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
  • Rare / orphan disease drugs
  • Auto-immune
  • Vaccine
  • Cell-therapy
  • Multi-specific antibodies
  • CVD
  • AstraZeneca
  • Hengrui Pharmaceuticals
  • SHA: 600276
  • Diabetes
Insilico Medicine and Luoxin Pharmaceutical Forge Long‑Term Strategic Collaboration on AI‑Enabled Drug Discovery in Chronic Diseases
CompanyDeals

Insilico Medicine and Luoxin Pharmaceutical Forge Long‑Term Strategic Collaboration on AI‑Enabled Drug Discovery in Chronic Diseases

Insilico Medicine (HKG: 3696), an AI‑powered drug discovery company, and China‑based Luoxin Pharmaceutical Group Co., Ltd. (SHE: 002793) jointly announced that they have entered into a long‑term strategic collaboration on…

November 16, 2026
CHMP Recommends Roche's Gazyva for Lupus – Obinutuzumab Poised to Become Add‑On Therapy for Moderate‑to‑Severe SLE in the EU

CHMP Recommends Roche’s Gazyva for Lupus – Obinutuzumab Poised to Become Add‑On Therapy for Moderate‑to‑Severe SLE in the EU

November 16, 2026
CHMP Backs Innovent Biologics' Sintilimab – PD‑1 Immunotherapy Recommended for EU Approval in Advanced Non‑Squamous NSCLC

CHMP Backs Innovent Biologics’ Sintilimab – PD‑1 Immunotherapy Recommended for EU Approval in Advanced Non‑Squamous NSCLC

November 16, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Raytone Bio Completes Angel Round to Advance iSus® Platform
Company

Raytone Bio Completes Angel Round to Advance iSus® Platform

January 18, 2025
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up